Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2018 Jan:115:97-102.
doi: 10.1016/j.lungcan.2017.11.024. Epub 2017 Nov 24.

How does autoimmune disease impact treatment and outcomes among patients with lung cancer? A national SEER-Medicare analysis

Saad A Khan  1 , Sandi L Pruitt  2 , Lei Xuan  3 , Una Makris  4 , David E Gerber  5
Affiliations

How does autoimmune disease impact treatment and outcomes among patients with lung cancer? A national SEER-Medicare analysis

Saad A Khan et al. Lung Cancer. 2018 Jan.

Abstract

Background: The advent of cancer immunotherapy has made autoimmune disease in oncology populations clinically important. We analyzed the association of autoimmune disease with treatment and outcomes among lung cancer patients.

Methods: Using linked Surveillance Epidemiology and End Results (SEER)-Medicare data, we identified lung cancer patients diagnosed between 1992 and 2009 with autoimmune diseases. We recorded number and timing of autoimmune disease diagnoses, lung cancer treatment, and markers of healthcare utilization including emergency department visits, hospitalizations, and outpatient visits. To account for potential lead-time bias, we used a matched case-control analysis wherein living and deceased patients were matched on survival time. We performed unadjusted and multivariable adjusted logistic regressions separately by cancer stage for all-cause and lung cancer-specific mortality.

Results: Among 172,285 lung cancer patients, 23,084 (13.4%) had ≥1 autoimmune disease at any time. Overall, 10,927 patients (6.3%) had one autoimmune disease before cancer diagnosis; 9338 (5.4%) had two or more before cancer diagnosis; and 2819 (1.6%) had one or more after cancer diagnosis. Healthcare utilization was higher in the autoimmune disease population. Lung cancer treatment patterns were similar among patients with and without autoimmune disease and there was no significant association with mortality.

Conclusions: Among patients with lung cancer, autoimmune disease does not influence treatment patterns and is not associated with mortality.

Keywords: Autoimmune disease; Immune therapy; Lung cancer; SEER-medicare.

PubMed Disclaimer

Conflict of interest statement

Disclosure: all authors report no conflict of interest.

Figures

Figure 1
Figure 1
Odds of death among lung cancer patients by the number and timing of diagnosed autoimmune diseases, compared to those with no diagnosed autoimmune conditions, separately by lung cancer stage at diagnosis.
Figure 1
Figure 1
Odds of death among lung cancer patients by the number and timing of diagnosed autoimmune diseases, compared to those with no diagnosed autoimmune conditions, separately by lung cancer stage at diagnosis.
See this image and copyright information in PMC

References

    1. de Visser KE, Eichten A, Coussens LM. Paradoxical roles of the immune system during cancer development. Nat Rev Cancer. 2006;6(1):24–37. - PubMed
    1. Graus F, et al. Anti-Hu antibodies in patients with small-cell lung cancer: association with complete response to therapy and improved survival. J Clin Oncol. 1997;15(8):2866–72. - PubMed
    1. Dantal J, et al. Effect of long-term immunosuppression in kidney-graft recipients on cancer incidence: randomised comparison of two cyclosporin regimens. Lancet. 1998;351(9103):623–8. - PubMed
    1. Miao Y, et al. De novo cancers arising in organ transplant recipients are associated with adverse outcomes compared with the general population. Transplantation. 2009;87(9):1347–59. - PubMed
    1. Bongartz T, et al. Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials. JAMA. 2006;295(19):2275–85. - PubMed

Publication types